ArticleExploration of medicine2025

Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens.

Apostolos P Georgopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.